AuraSense Therapeutics, LLC: Series B $5.4M

Posted in I - Series B, Q - 4Q11, R - MID WEST, X - Cardiology, X - Dermatology, X - Neurology, X - Oncology, XX - IL

AuraSense Therapeutics (Evanston, IL) a development-stage biotechnology company focused on nucleic acid constructs for heart disease, cancer, skin conditions and bacterial infection, closed a $4.5M Series B financing. Participants include Abbott Biotech Ventures.

Naurex, Inc.: Series A $18M

Posted in I - Series A, Q - 2Q11, R - MID WEST, X - CNS, X - Depression, XX - IL

Naurex (Evanston, IL) a clinical-stage pharmaceutical company focused on depression and other CNS-related disorders, closed a $18M Series A financing. Participants include Adams Street Partners, Latterell Venture Partners, Druid BioVentures, Genesys Capital, PathoCapital, Lundbeck, Takeda Ventures and Shire.

NanoInk, Inc.: Series E $65M

Posted in I - Series E, Q - 4Q10, R - MID WEST, X - Biologics Mfg., XX - IL

NanoInk (Skokie, IL) a commercial-stage a protein analysis, biomaterial manufacturing and biodiscovery assay kit developer, closed a$65M Series E financing. Participants include Lurie Investment Fund.

Coskata, Inc.: Series D $23.7M

Posted in I - Series D, Q - 2Q10, R - MID WEST, X - Biofuel, XX - IL

Coskata (Warrenville, IL) a development-stage bacterial fermentation biofuels company closed a $23.7M Series D financing. Participants include Total, Blackstone Group, Advanced Technology Ventures, Globespan Capital Partners, General Motors, GreatPoint Ventures and Khosla Ventures.

NeuroTherapeutics Pharma, Inc.: Series B $43M

Posted in I - Series B, Q - 2Q10, R - MID WEST, X - CNS, X - Epilepsy, X - Pain, XX - IL

NeuroTherapeutics Pharma (Chicago, IL) a clinical-stage biopharmaceutical company focused on the CNS disorders of epilepsy, acute and neuropathic pain, closed a $43M Series B financing. Participants include Fidelity Biosciences, MPM Capital, S.R. One, Pfizer, Novo Ventures and Thomas McNerney & Partners.

Sagent Pharmaceuticals, Inc.: Series A $30M

Posted in I - Series A, Q - 2Q09, R - MID WEST, X - Injectable, X - Therapeutic Platform, XX - IL

Sagent Pharmaceuticals (Schaumberg, Illinois) commercial-stage specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products, closed a $30M Series A financing, bringing the total round to $113M. Participants include Vivo Ventures.

to top of page...